---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125384"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:04:16.182765+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Olema Pharma Q3 net loss $34.6M; cash $214.8M; OP-3136 IND on track

## Summary
- Q3 2024 net loss $34.6M vs $21.5M in Q3 2023; GAAP R&D $33.2M (up from $19.5M).
- Cash, equivalents, marketable securities $214.8M as of Sep 30, 2024; no revenue reported.
- OPERA-01 Phase 3 palazestrant monotherapy enrolling; top-line readout expected 2026.
- IND submission for KAT6 inhibitor OP-3136 expected before year-end; Phase 1 start early 2025.
- Updated Phase 2 palazestrant + ribociclib data to be presented at SABCS December 2024.

## SEC filing metadata
- accession: 0000950170-24-125384
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017024125384/0000950170-24-125384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017024125384/olma-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125384
- JSON: https://secwatch.observer/filing/0000950170-24-125384.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125384.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.